These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 26201030)

  • 21. Neuroanatomical underpinnings of autism symptomatology in carriers and non-carriers of the 22q11.2 microdeletion.
    Gudbrandsen M; Bletsch A; Mann C; Daly E; Murphy CM; Stoencheva V; Blackmore CE; Rogdaki M; Kushan L; Bearden CE; Murphy DGM; Craig MC; Ecker C
    Mol Autism; 2020 Jun; 11(1):46. PubMed ID: 32513259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated genome-wide Alu methylation and transcriptome profiling analyses reveal novel epigenetic regulatory networks associated with autism spectrum disorder.
    Saeliw T; Tangsuwansri C; Thongkorn S; Chonchaiya W; Suphapeetiporn K; Mutirangura A; Tencomnao T; Hu VW; Sarachana T
    Mol Autism; 2018; 9():27. PubMed ID: 29686828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hierarchical cortical transcriptome disorganization in autism.
    Lombardo MV; Courchesne E; Lewis NE; Pramparo T
    Mol Autism; 2017; 8():29. PubMed ID: 28649314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring key genes and pathways associated with sex differences in autism spectrum disorder: integrated bioinformatic analysis.
    Nautiyal H; Jaiswar A; Jha PK; Dwivedi S
    Mamm Genome; 2024 Jun; 35(2):280-295. PubMed ID: 38594551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thalamic miR-338-3p mediates auditory thalamocortical disruption and its late onset in models of 22q11.2 microdeletion.
    Chun S; Du F; Westmoreland JJ; Han SB; Wang YD; Eddins D; Bayazitov IT; Devaraju P; Yu J; Mellado Lagarde MM; Anderson K; Zakharenko SS
    Nat Med; 2017 Jan; 23(1):39-48. PubMed ID: 27892953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neural substrates of psychosis revealed by altered dependencies between brain activity and white-matter architecture in individuals with 22q11 deletion syndrome.
    Bortolin K; Delavari F; Preti MG; Sandini C; Mancini V; Mullier E; Van De Ville D; Eliez S
    Neuroimage Clin; 2022; 35():103075. PubMed ID: 35717884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling a model: Mouse genetics, 22q11.2 Deletion Syndrome, and disorders of cortical circuit development.
    Meechan DW; Maynard TM; Tucker ES; Fernandez A; Karpinski BA; Rothblat LA; LaMantia AS
    Prog Neurobiol; 2015 Jul; 130():1-28. PubMed ID: 25866365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring pathway interactions to detect molecular mechanisms of disease: 22q11.2 deletion syndrome.
    Shin W; Kutmon M; Mina E; van Amelsvoort T; Evelo CT; Ehrhart F
    Orphanet J Rare Dis; 2023 Oct; 18(1):335. PubMed ID: 37872602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct neurocognitive profiles and clinical phenotypes associated with copy number variation at the 22q11.2 locus.
    O'Hora KP; Kushan-Wells L; Schleifer CH; Cruz S; Hoftman GD; Jalbrzikowski M; Gur RE; Gur RC; Bearden CE
    Autism Res; 2023 Dec; 16(12):2247-2262. PubMed ID: 37997544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robust and replicable functional brain signatures of 22q11.2 deletion syndrome and associated psychosis: a deep neural network-based multi-cohort study.
    Supekar K; de Los Angeles C; Ryali S; Kushan L; Schleifer C; Repetto G; Crossley NA; Simon T; Bearden CE; Menon V
    Mol Psychiatry; 2024 Oct; 29(10):2951-2966. PubMed ID: 38605171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrative transcriptome network analysis of iPSC-derived neurons from schizophrenia and schizoaffective disorder patients with 22q11.2 deletion.
    Lin M; Pedrosa E; Hrabovsky A; Chen J; Puliafito BR; Gilbert SR; Zheng D; Lachman HM
    BMC Syst Biol; 2016 Nov; 10(1):105. PubMed ID: 27846841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium.
    Gur RE; Bassett AS; McDonald-McGinn DM; Bearden CE; Chow E; Emanuel BS; Owen M; Swillen A; Van den Bree M; Vermeesch J; Vorstman JAS; Warren S; Lehner T; Morrow B
    Mol Psychiatry; 2017 Dec; 22(12):1664-1672. PubMed ID: 28761081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disrupted working memory circuitry and psychotic symptoms in 22q11.2 deletion syndrome.
    Montojo CA; Ibrahim A; Karlsgodt KH; Chow C; Hilton AE; Jonas RK; Vesagas TK; Bearden CE
    Neuroimage Clin; 2014; 4():392-402. PubMed ID: 24567911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Examining the Overlap between Autism Spectrum Disorder and 22q11.2 Deletion Syndrome.
    Ousley O; Evans AN; Fernandez-Carriba S; Smearman EL; Rockers K; Morrier MJ; Evans DW; Coleman K; Cubells J
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low prevalence of substance use in people with 22q11.2 deletion syndrome.
    Vingerhoets C; van Oudenaren MJF; Bloemen OJN; Boot E; van Duin EDA; Evers LJM; Fiksinski AM; Breetvelt EJ; Palmer LD; Vergaelen E; Vogels A; Meijer C; Booij J; ; de Haan L; Swillen A; Vorstman JAS; Bassett AS; van Amelsvoort TAMJ
    Br J Psychiatry; 2019 Nov; 215(5):661-667. PubMed ID: 30604657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interaction between neurocognitive functioning, subthreshold psychotic symptoms and pharmacotherapy in 22q11.2 deletion syndrome: A longitudinal comparative study.
    Weinberger R; Weisman O; Guri Y; Harel T; Weizman A; Gothelf D
    Eur Psychiatry; 2018 Feb; 48():20-26. PubMed ID: 29331595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Favorable effects of omega-3 polyunsaturated fatty acids in attentional control and conversion rate to psychosis in 22q11.2 deletion syndrome.
    Armando M; Ciampoli M; Padula MC; Amminger P; De Crescenzo F; Maeder J; Schneider M; Schaer M; Managò F; Eliez S; Papaleo F
    Neuropharmacology; 2020 May; 168():107995. PubMed ID: 32057798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Episodic Future Thinking in Autism Spectrum Disorder and 22q11.2 Deletion Syndrome: Association with Anticipatory Pleasure and Social Functioning.
    Feller C; Dubois C; Eliez S; Schneider M
    J Autism Dev Disord; 2021 Dec; 51(12):4587-4604. PubMed ID: 33586083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cortical Dysconnectivity Measured by Structural Covariance Is Associated With the Presence of Psychotic Symptoms in 22q11.2 Deletion Syndrome.
    Sandini C; Scariati E; Padula MC; Schneider M; Schaer M; Van De Ville D; Eliez S
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2018 May; 3(5):433-442. PubMed ID: 29735153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal trajectories of cortical thickness as a biomarker for psychosis in individuals with 22q11.2 deletion syndrome.
    Ramanathan S; Mattiaccio LM; Coman IL; Botti JC; Fremont W; Faraone SV; Antshel KM; Kates WR
    Schizophr Res; 2017 Oct; 188():35-41. PubMed ID: 27988073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.